血管靶向抗肿瘤药物临床试验中对心血管毒性的监测和防治  

Monitoring and controlling the cardiovascular toxicity of vascular targeting anticancer drugs in clinical trials

作　　者：张倩[1] 郭婷婷[1] 周宇子 王璐 华潞[1] 

机构地区：[1]中国医学科学院北京协和医学院阜外心血管病医院卫生部心血管药物临床研究重点实验室,北京100037 [2]中石油燃料油有限责任公司质量环保处职业健康管理,北京100102

出　　处：《中国新药杂志》2015年第1期59-63,117,共6页Chinese Journal of New Drugs

摘　　要：血管靶向抗肿瘤药物的出现,标志着肿瘤治疗进入新的纪元。但是由于血管靶向抗肿瘤药物选择性作用于肿瘤血管,也带来了临床试验中重要的临床安全问题—其潜在的心血管不良反应。通过对血管靶向抗肿瘤药物可能产生的心血管不良反应及发生机制的分析,提出如何正确应对血管靶向肿瘤药物临床试验中心血管毒性作用的预防及治疗。The appearance of vascular targeting anticancer drugs marks the cancer treatment into a new era. However, due to the selectivity to the tumor blood vessels of vascular targeting anticancer drugs, the important safety issue of their clinical trials is the potential cardiovascular side effects. Through analyzing the cardiovascular adverse reactions of vascular targeting anticancer drugs and their mechanisms, we proposed how to deal with the cardiovascular toxic effects of vascular targeting anticancer drugs.

关 键 词：血管靶向抗肿瘤药物 药物临床试验 心血管毒性 

分 类 号：R969.4[医药卫生—药理学]